AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01090154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cimzia
Description: Cimzia 400mg administered via two 200mg subcutaneous injections at weeks 0, 2, and 4; followed by every 4 week dosing.
Study NCT01313494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: Roflumilast tablets
Study NCT01313494 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study NCT01313494 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Salbutamol
Description: Salbutamol (given by MDI and spacer) used as rescue medication on an ass needed basis throughout the trial, and was used for post-bronchodilator spirometry tests at all study visits.
Study NCT01313494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Salbutamol (given by MDI and spacer) used as rescue medication on an ass needed basis throughout the trial, and was used for post-bronchodilator spirometry tests at all study visits.
Study NCT04160572 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Morning sleep schedule
Description: sleep right after night shifts
Study NCT04160572 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Morning sleep schedule
Description: sleep right after night shifts
Study NCT04160572 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Evening sleep schedule
Description: sleep before night shifts
Study NCT04160572 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evening sleep schedule
Description: sleep before night shifts
Study NCT01298141 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: agalsidase alfa
Description: Cohort 1: 0.2 mg/kg body weight administered as an intravenous (IV) infusion over 40 minutes every other week (EOW)~Cohort 2: 0.2 mg/kg body weight administered as an intravenous (IV) infusion over 40 minutes weekly
Study NCT04064541 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Virtual Visit
Description: Virtual Visit
Study NCT04791605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait analysis
Description: Kinematic and kinetic analysis
Study NCT03415659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HWH340 tablet
Description: 1. single escalating dose study starts from 20 mg as the initial dose until the maximum dose group (520mg) or maximum tolerated dose (MTD) has been reached.~2. multiple-dose study conducted on oral HWH340 tablet BID. The DLTs evaluating period is 4 weeks and the safety evaluation period lasts till 4 weeks after drug withdrawal.~3. dose-expansion study conducted on oral HWH340 tablet BID in 2 to 4 dose groups. Patients with BRCA mutation OR HRD will be assigned to 2 cohort in each dose group.
Study NCT02737228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG200745 PPA
Description: CG200745 PPA IV every week three times per cycle (4 weeks)
Study NCT02737228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m\^2 intravenously every week three times per cycle (4 weeks)
Study NCT02737228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 100 mg per oral daily per cycle (4 weeks)
Study NCT02611128 — intervention group
Intervention type: OTHER
Intervention: Phenotype/genotype assessment
Description: The investigators will perform careful phenotyping in addition to hormonal assessments and assessments of DENND1A
Study NCT03168919 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fractionated Radiation
Description: Standard of care fractionated radiation therapy will be given to the tumor.
Study NCT03168919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Standard of care temozolomide will be given along with radiation therapy
Study NCT03168919 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Four MRI scan will be performed according to the protocol. The first one will be obtained before start of radiation therapy, the second MRI will be obtained after completion of 20 +/- 4 Gy, the third MRI will be obtained after completion of 40 +/- 4 Gy, and the final MRI will be obtained after completion of the radiation therapy.
Study NCT01273740 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: External support
Description: Bypass surgery with externally supported graft
Study NCT04122664 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RayOne® Hydrophobic lens 800C
Description: Patients will receive a monofocal, aspheric, hydrophobic acrylic intraocular lens: the RayOne® Hydrophobic lens 800C
Study NCT04122664 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RayOne® Hydrophilic lens 600C
Description: Patients will receive a monofocal aspheric, hydrophilic acrylic intraocular lens: the RayOne® Hydrophilic lens 600C.
Study NCT02851056 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Survivin Vaccine
Description: Pre-transplant vaccination : The target dose of Survivin+ Dendritic cells (survivin+, CD11c+, Human Leukocyte Antigen - antigen D Related (HLA-DR)+ by flow-cytometry) is 15 x 10\^6 cells. A minimum of 1 x 10\^6 cells and a maximum of 20 x 10\^6 cells will be administered.~Post-transplant vaccination: The target dose of Survivin+ Dendritic cells (survivin+, CD11c+, HLA-DR+ by flow-cytometry) is 15 x 10\^6 cells. A minimum of 1 x 10\^6 cells and a maximum of 20 x 10\^6 cells will be administered.
Study NCT02851056 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Cell Transplantation
Description: The participant's own cells are collected from their blood, frozen, and then given back to them after they receive chemotherapy.
Study NCT02851056 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar 13
Description: 13-Valent Pneumococcal Conjugate Vaccine (PCV13, Prevnar13). Co-Immunization: All participants will be co-immunized with Prevnar at each time they receive the survivin vaccine. This vaccine will be administered intramuscular (IM) 0.5cc.
Study NCT02851056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony Stimulating Factor
Description: After the first survivin vaccination, participants will be mobilized with G-CSF.
Study NCT01005888 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C1 esterase inhibitor [human] (C1INH-nf)
Study NCT01005888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (saline)
Study NCT00367484 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rebif® (clone 484-39)
Description: s.c. administered Rebif®
Study NCT03408249 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: IBDoc calprotectin test
Description: Patients are asked to perform a single IBDoc calprotectin home test.
Study NCT03408249 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire
Description: Patients evaluate the ease-of-use of the test, clearness of test results and comprehensiveness of the instructions for use through a specific questionnaire implementing Likert scales.
Study NCT02526875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telminuvo®Tab. 40/2.5mg
Description: per oral for 8weeks after 2\~4weeks run-in period with Telmitrend®Tab. 40mg
Study NCT02526875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telminuvo®Tab. 40/2.5mg
Description: per oral for 8weeks after 2\~4weeks run-in period with Telmitrend®Tab. 40mg
Study NCT04919876 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fruit/vegetable supplement (FVS)
Description: The supplement contains polyphenols, carotenoids, and other phytochemicals present in plant foods.
Study NCT04919876 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The product does not contain nutrients present in the FVS.
Study NCT02616315 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naltrexone HCl/Bupropion HCl Placebo
Description: Naltrexone/bupropion placebo-matching tablets
Study NCT02616315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone HCl/Bupropion HCl
Description: Naltrexone HCl 8 mg/bupropion HCl 90 mg tablets
Study NCT03294291 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus lumborum block
Description: Postoperative pain procedure
Study NCT03294291 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal block
Description: Postoperative pain procedure
Study NCT04380012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Pyrotinib as interventions were used in patients with HER2-positive advanced colorectal cancer
Study NCT05139576 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: serum 25OHD testing
Description: Subjects tested for serum 25OHD between April 2020 to March 2021 was reviewed daily and those with 25OHD levels >150 ng/ml were contacted via telephone.
Study NCT01514630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate
Description: Five grams of creatine monohydrate will be administered for eight weeks.
Study NCT03022045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: risankizumab administered by subcutaneous injection
Study NCT02315079 — intervention group
Intervention type: OTHER
Intervention: Eye inflammation
Description: This group will have a regular eye exam with the collection of tears. In addition, a the Ocular Surface Disability Index Survey of National Eye Institute Visual Functioning Questionnaire- 25 may be administered.
Study NCT02315079 — intervention group
Intervention type: OTHER
Intervention: Without eye inflammation
Description: This group will have a regular eye exam with the collection of tears.
Study NCT02127814 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lactobacillus reuteri
Description: One chewable tablet of 1E8 CFU L. reuteri, once per day
Study NCT02127814 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri
Description: One chewable tablet of 1E8 CFU L. reuteri, once per day
Study NCT01447251 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PreDx Diabetes Risk Score
Description: The PreDx DRS measures 7 predictive biomarkers -Adiponectin, C-reactive protein (CRP), Ferritin, Glucose, Insulin, IL-2 and HbA1c, using a proprietary algorithm a risk score in order to calculate a risk score. There are three risk strata, with low risk defined as PreDx DRS \<4.5, moderate risk as PreDx DRS ≥4.5 and \<8.0, and high risk as PreDx DRS ≥8.0.
Study NCT01447251 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PreDx Diabetes Risk Score
Description: The PreDx DRS measures 7 predictive biomarkers -Adiponectin, C-reactive protein (CRP), Ferritin, Glucose, Insulin, IL-2 and HbA1c, using a proprietary algorithm a risk score in order to calculate a risk score. There are three risk strata, with low risk defined as PreDx DRS \<4.5, moderate risk as PreDx DRS ≥4.5 and \<8.0, and high risk as PreDx DRS ≥8.0.
Study NCT04380012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib in combination with trastuzumab
Description: Pyrotinib in combination with trastuzumab as interventions were used in patients with HER2-positive advanced colorectal cancer
Study NCT01573416 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ASSIST-linked brief intervention for hazardous and harmful substance use.
Description: ASSIST-linked brief intervention will be applied to users achieving moderate risk scores in the ASSIST questionnaire. If after randomization are selected to enter the intervention group, they will receive a ten minute counseling carried immediately after the screening instrument. This intervention group will be re-evaluated after 3 months with the same ASSIST screening instrument.
Study NCT01573416 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Observation
Description: Subjects who obtain a moderate risk score in the ASSIST screening questionnaire and after randomization are selected for the control group, will receive a brochure with substance-abuse information without any further conversation about the subject with the caregiver. This observation group will be re-evaluated after 3 months with the same ASSIST screening instrument.
Study NCT02581228 — intervention group
Intervention type: DEVICE
Intervention: ML-PrediCare
Study NCT01398189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clozapine
Description: C-11 clozapine
Study NCT03634683 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LioCyx
Description: Autologous T cells transfected with mRNA encoding HBV antigen-specific TCR
Study NCT03861871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenfluramine Hydrochloride
Description: Oral aqueous solution of fenfluramine hydrochloride buffered to pH 5 and provided in concentrations of 2.5 mg/mL. Manufactured by Andersonbrecon, Inc. on behalf of Zogenix International Limited.
Study NCT00394433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT00394433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study NCT00394433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT00394433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Study NCT02920177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: platelet-rich plasma injection
Description: platelet-rich plasma injection
Study NCT02920177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kenalog 10 MG/ML Injectable Suspension
Description: 4 mL corticosteroid injection
Study NCT04104217 — intervention group
Intervention type: BEHAVIORAL
Intervention: Music therapy
Description: Music therapy sessions may last 20-60 minutes, with length and frequency to be determined mutually (generally 1-3 times per week). Music therapy sessions are done at the patient's bedside, where the music therapist plays live music on a guitar, keyboard, harp, or percussion instrument, sometimes as accompaniment to singing.
Study NCT04104217 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interviews
Description: Each interview will be conducted in person in a private setting (with the exception of caregivers, who have the option to conduct interviews over the phone if it is not feasible to take place in the hospital). Each interview will follow a semi-structured interview guide and will ask for consent to audio record the interviews .
Study NCT04306250 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apical prolapse fixation - anterior access
Description: The surgery is done in anterior access
Study NCT04306250 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Apical prolapse fixation - posterior access
Description: The surgery is done in posterior access
Study NCT02954185 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WellClub
Study NCT02954185 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy
Study NCT00741091 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carotid WALLSTENT Monorail Endoprosthesis
Description: A carotid artery stent for use in subjects at high risk for adverse events from Carotid endarterectomy (CEA) due to either anatomic or comorbid conditions who require carotid revascularization in the treatment of ipsilateral or bilateral carotid artery disease.
Study NCT00741091 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FilterWire EZ™ System™
Description: Embolic protection device used in conjunction with the Carotid WALLSTENT Endoprosthesis.
Study NCT01534780 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic ventral herniotomy
Description: Laparoscopy in general anesthesia are performed with placement of Physiomesh intraperitoneally. Fixation of the mesh is performed with 1 of 3 possible devices
Study NCT01534780 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Protack
Description: fixation of mesh with protack
Study NCT01534780 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Securestrap
Description: fixation of mesh with Securestrap
Study NCT01608958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: 10 IU oxytocin in 500 ml infusion
Study NCT01608958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: 10 IU oxytocin IM injection
Study NCT03383029 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iEAT Program
Description: The iEAT Program is a six-month long behavioral intervention consisting of 10 biweekly outpatient appointments of about 1 hour in length. The iEAT manual will guide behavioral intervention targeting severe feeding disorders and will involve some combination of escape extinction, reinforcement, and antecedent manipulation of food presentation to lessen the aversive quality of the meal.
Study NCT01906645 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care Transitions Innovation (C-TraIn)
Description: Multi-component transitional care intervention including transitional nursing care, pharmacy care, and medical home linkages
Study NCT01046071 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transversus abdominis plane block
Description: UL-guided TAP block with 20 ml of ropivacaine 0,5% bilateral, single dose.
Study NCT01046071 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: TAP block placebo
Description: UL-guided TAP block with 20 ml of saline bilaterally, single dose.
Study NCT03459521 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fendrix or HBVAXPRO 40
Description: To administer hepatitis B virus vaccines in patients with chronic liver disease that have not been previously vaccinated.
Study NCT04086719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Oral administration of tablet BMS- 986165
Study NCT04086719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrimethamine
Description: Oral administration of Pyrimethamine in combination with BMS-986185
Study NCT04491006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATH-1017
Description: Daily subcutaneous (SC) injection of ATH-1017 in a pre-filled syringe
Study NCT04491006 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily subcutaneous (SC) injection of Placebo in a pre-filled syringe
Study NCT04448925 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: inertial-load exercise (ILE)
Description: Length of time between exercise bouts
Study NCT01295788 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simultaneous RT-CGM and Pump Initiation
Description: Subjects in this group will start using RT-CGM at the same time as they initiate insulin pump therapy.
Study NCT01295788 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Initiation of RT-CGM
Description: Subjects in this group will start using RT-CGM 6 months after initiation of insulin pump therapy.
Study NCT03193216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alginates
Description: Liquid Alginate therapy will be added to twice daily PPI regimen. Patients will be asked to take the alginate solution four times daily (following meals and at bedtime) at 10ml/dose.
Study NCT01724047 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Playground Intervention
Description: Intervention is designed for children diagnosed with an autism spectrum disorder (ASD) included in a regular education k through fifth grade classroom for at least 50% of the school day. Schools will be randomized to one of two conditions. The conditions are: 1) Immediate treatment, where the training will begin immediately after baseline measures are completed. 2) Waitlist treatment, where the training will begin the following school year. This study will take place at school. All intervention activities will be conducted during recess or lunch where children with autism may have the most difficulty interacting with peers. A total of 14-16 intervention sessions will be held with the child with autism, school personnel, and the child's classmates. The intervention will last approximately 3 months with a 3-month follow-up.
Study NCT01724047 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STAT Intervention
Description: This study will track the behavioral progress of children whose teachers receive training in these instructional methods. This study also will examine the ability and willingness of teachers to use these methods as they were designed. The study will last approximately 18 weeks (6 weeks of intervention, and a 3 month follow up visit). This study will take place at school. Classrooms will be randomized to one of two conditions. The conditions are: 1) Immediate treatment, where the training will begin immediately after baseline measures are completed. 2) Waitlist treatment, where the training will begin the following school year. All intervention activities will be conducted with a teacher during the school day but not during instructional time. Study staff will visit the school on a weekly basis to train your child's teacher on evidence-based strategies for teaching children with autism.